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Shi-Liu-Wei-Liu-Qi-Yin (SLWLQY) was traditionally used to treat cancers. However, scientiﬁc evidence of the anticancer eﬀects
still remains undeﬁned. In this study, we aimed to clarify the possible mechanisms of SLWLQY in treating cancer. We evaluated
the eﬀects of SLWLQY on apoptosis-related experiments inducing in TSGH-8301 cells by (i) 3-(4,5-dimethylthiazol-zyl)-2,5-
diphenylterazolium bromide (MTT) for cytotoxicity; (ii) cell-cycle analysis and (iii) western blot analysis of the G2/M-phase
and apoptosis regulatory proteins. Human bladder carcinoma TSGH-8301 cells were transplanted into BALB/c nude mice as
a tumor model for evaluating the antitumor eﬀect of SLWLQY. Treatment of SLWLQY resulted in the G2/M phase arrest and
apoptotic death in a dose-dependent manner, accompanied by a decrease in cyclin-dependent kinases (cdc2) and cyclins (cyclin
B1). SLWLQY stimulated increases in the protein expression of Fas and FasL, and induced the cleavage of caspase-3, caspase-9
and caspase-8. The ratio of Bax/Bcl2 was increased by SLWLQY treatment. SLWLQY markedly reduced tumor size in TSGH-8301
cells-xenografted tumor tissues. In the tissue specimen, SLWLQY up-regulated the expression of Fas, FasL and Bax proteins, and
down-regulated Bcl2 as well as in in vitro assay. Our results showed that SLWLQY reduced tumor growth, caused cell-cycle arrest
and apoptosis in TSGH-8301 cells via the Fas and mitochondrial pathway.
1.Introduction
Orientalherbalmedicineshavebeenusedsinceancienttimes
to treat malignancies. Systematic characterization of active
phytochemicals in medicinal herbs and their mechanisms of
action are important for providing the rationale for their
eﬃcacy and for transforming herbal practices into evidence-
based medicine [1]. Typical traditional Chinese medicines
consist of 5–16 components that are mixed to minimize side
eﬀectsandmaximizemedicaleﬀects.Recently,therehasbeen
increasing interest in the biological activity of traditional
medicines, and numerous studies support their potential
clinical beneﬁt for diseases that are diﬃcult to treat such
ascancer[2–5].Shi-Liu-Wei-Liu-Qi-Yin(SLWLQY)formula
is a prescription for patients with various tumors and is
composed of 16 oriental medicinal herbs such as Panax
Ginseng C.A., Astragalus Membranaceus, Paeonia lactiﬂora
Pall, Angelica Sinensis Diels, and so forth (Table 1).
The majority of bladder cancers (90%) are transi-
tional cell carcinoma (TCC). Transitional cell carcinoma,
occurring in the renal pelvis, ureter, urinary bladder and
urethra, is the most serious cancer of the urinary tract
[6]. Recent studies have begun to elucidate the underlying
genetic determinations of the morphologic and biologic
characteristics of these diﬀerent forms of bladder cancer
[7]. The molecular alterations that precede morphologic
changes and are responsible for tumorigenesis and pro-
gression of bladder cancer also include alterations in cell-
cycle regulators causing uncontrolled cancer growth [8].
In general, the progression of cell cycle is a complex
process involving resting G0 phase, and cell growth involving
G1, S and G2/M phase in eukaryotes [9]. The cell-cycle
phases receive diﬀerent growth controlling signals that are
processed for the activation of diﬀerent members of the
cyclin-dependentkinases(CDKs)[10,11].Cyclin-dependent
kinases are governed by their regulatory subunits known2 Evidence-Based Complementary and Alternative Medicine
as cyclins, and are activated at a speciﬁc phase of the cell
cycle.
In this study, we aimed to study new approaches that
could alter uncontrolled human bladder TCC growth by
modulating cell-cycle regulators causing cell-cycle arrest and
could be useful in human bladder cancer prevention. We
assessed the eﬃcacy of SLWLQY on cell growth, cell-cycle
progressionandapoptoticdeathinhumanbladderTCCcell-
line-TSGH-8301. The results obtained clearly demonstrate
that SLWLQY inhibits human bladder TCC cell growth,
causes cell-cycle arrest and apoptosis, and that a strong
decrease in both Cdc2 and cyclinB1 levels are responsible
for the observed eﬀects of SLWLQY in cell-cycle arrest.
Furthermore, SLWLQY caused caspase-3, caspase-9 and
caspase-8 cleavages contribute to its apoptotic response in
TSGH-8301 cells.
2. Methods
2.1. Reagents. Tris-HCl, EGTA, SDS, bovine serum albumin
(BSA), Nonidet P-40, dimethyl sulfoxide (DMSO), RNase
A and polyclonal antibody against α-actin were purchased
from Sigma Chemical Co. (St Louis, MO). Minimum essen-
tial medium (MEM), Dulbecco’s modiﬁed Eagle medium
(DMEM), RPMI medium 1640, F-12 nutrient mixture, fetal
bovine serum (FBS), penicillin–streptomycin mixed antibi-
otics, l-glutamine, Dulbecco‘s phosphate buﬀer solution
(PBS) and trypsin–EDTA, were purchased from Gibco/BRL
(Gaithersburg, MD). Antibodies against Bcl-2, Bax, caspase
3, caspase 8, Fas, fasL, cyclinB1 and Cdc2 were from Santa
Cruz (Santa Cruz, CA). The enhanced chemiluminescence
(ECL) kit was purchased from Amersham Life Science
(Amersham, UK).
2.2. Preparation of SLWLQY Extract. The SLWLQY prescrip-
tion consists of 16 diﬀerent medical plant ingredients as
shown in Table 1. All of the herbs were purchased from
Changhwa in Taiwan. To prepare the aqueous extract of
SLWLQY, 455g of dried materials was extracted with 3l of
boiling water for 2h. The prepared extract was freeze-dried
and dissolved in distilled water, ﬁltered and stored at −20◦C
untiluse.Theaverageyieldofdriedextractwasabout16.3%.
2.3. HPLC Assay for SLWLQY. The components of SLWLQY
were determined by HPLC analysis using a Hewlett-
Packard Vectra 436/33N system with a diode array detec-
tor. The HPLC method employed a 5μmR P - 1 8c o l u m n
(4.6×150mm i.d.). The SLWLQY were ﬁltered through a
0.45μm ﬁlter disc and 10μl were injected onto the column.
The chromatography was monitored at 280nm, and UV
spectra were collected to conﬁrm peak purity. The mobile
phase contained two solvents (A, formic acid/water=10:90;
B,formicacid/water/acetonitrile=10:60:30)runbyalinear
gradient method at room temperature as follows: from 20%
B to 85% B (ﬂow rate=0.8mlmin−1) over 55min.
2.4. Cell Line and Cell Culture. Human urinary bladder
cancer cells (TSGH-8301) were maintained in RPMI 1640
Table 1: The composition of SLWLQY.
Scientiﬁc name Grams
(1) Panax Ginseng C.A. Mayer 50
(2) Astragalus Membranaceus 50
(3) Glycyrrhiza Uralensis Fisch 12.5
(4) Angelica Sinensis (Oliv.) Diels 50
(5) Paeonia lactiﬂora Pall 50
(6) Aucklandia lappa Decne 20
(7) Citrus aurantium L.2 5
(8) Areca catechu Linn 12.5
(9) Cortex Magnoline Oﬃcinalis 20
(10) Linderae Radix 20
(11) Cinnamomum cassia presl 20
(12) Saposhnikovia divaricata (Turcz.) Schischk 25
(13) Perilla frutescens (Linn.) Britt. 25
(14) Angelicae Dahuricae Radix 25
(15) Ligustici Rhizoma 25
(16) Platycodon grandiﬂorum A. DC 25
medium. TSGH-8031 cells were derived from a well-
diﬀerentiated human TCC of the urinary bladder [12], hav-
ing wt p53 but mutant Rb gene. Human gastric carcinoma
(AGS) were maintained in F-12 nutrient mixture medium;
adenocarcinoma MCF-7 and human oral epidermoid carci-
noma KB were maintained in MEM; and hepatocarcinoma
Huh-7 and human fetal liver cells WRL-68 were maintained
in Dulbecco’s modiﬁed Eagle’s medium. Cells were cultured
at 37◦Ci n5 %C O 2 in medium supplemented with 10% FBS
and antibiotics (100Uml−1 of penicillin and 100μgml −1
of streptomycin). All of the cell lines were purchased from
BCRC, Hsinchu, Taiwan.
2.5. Assessment of Cell Viability. Cells were seeded at a
density of 1×105 cellsml−1 and incubated with SLWLQY at
various concentrations (0–5mgml−1) for 24h. Thereafter,
the medium was changed and 3-(4,5-dimethylthiazol-zyl)-
2, 5-diphenylterazolium bromide (MTT, 0.5mgml−1)w a s
added to incubate for 4h. The viable cell was directly
proportional to the production of formazan. Following
dissolutioninisopropanol,theresultwasreadat563nmwith
a spectrophotometer (Beckman DU640).
2.6. Flow Cytometry Analysis. Cell-cycle analysis was per-
formedwithaﬂowcytometer(FACSCalibur;BDBioscience,
CA, USA). Cells were cultured in 6cm culture plates and
treated with various concentrations of SLWLQY for 24h.
Thereafter, cells were washed twice with cold PBS solution.
Then the cell suspension was centrifuged at 1500g for
5min, ﬁxed and permeabilized with 70% ethanol at −20
◦C
overnight. Prior to the samples being analyzed by the ﬂow
cytometry, 1ml of cold propidium iodide (PI) stain solution
(20μgml −1 PI, 20μgml −1 RNase A and 0.1% Triton X-100)
was added to the mixture and it was incubated for 15min in
darkness at room temperature. Data acquisition and analysis
were performed in the ﬂow cytometer with accompanyingEvidence-Based Complementary and Alternative Medicine 3
software (CellQuest; BD Bioscience, CA). The percentage
of hypodiploid cells (sub G1 phase) over total cells was
calculated and represented as percent of apoptosis.
2.7. Western Blot Analysis. After treatment with the desired
concentration of the SLWLQY for 24h, the medium was
removed and rinsed with PBS at room temperature. Then
0.5ml of cold RIPA buﬀers (1% NP-40, 50mM Tris–base,
0.1% SDS, 0.5% deoxycholic acid, 150mM NaCl, pH 7.5)
with fresh protease inhibitor was added. Cells were scraped
and the lysate was centrifuged at 10000g for 10min.
Cell lysate (50μg) was mixed with an equal volume of
electrophoresis sample buﬀer and then boiled for 10min,
followedby analysisusing SDS–PAGE andtransferofprotein
was from the gel to nitrocellulose membrane (Millipore,
Bedford, MA) by using electroblotting apparatus. Then the
proteinswereaddedwiththeECLWesternblottingdetection
reagents (Amersham Biosciences, USA) and analyzed using
the Fui LAS-3000 imaging system (Japan). The antibodies
used in this study included caspase-3, caspase-8, Bax, Bcl-2,
Fas and FasL (Santa Cruz Biotech) anti-Cyclin B1 and anti-
Cdc2 (Upstate), and anti-β-actin (Sigma Chemical Co).
2.8. Preparation for Cytosolic and Mitochondrial Fraction.
Subcellular fraction was isolated by using Mitochondria
Isolation Kit (Pierce, USA) to separate mitochondrion from
cytosolic components. Cytochrome c existing in the two
fractions was analyzed by western blot.
2.9. siRNA Transfection. RNA interference of Fas was per-
formed using 19bp siRNA duplexes purchased from Dhar-
macon (Thermo Scientiﬁc). The coding strand for Fas
siRNA was GAACAUGGAAUCAUCAAGG. For transfection,
TSGH-8301cellswereseededin6-wellplatesandtransfected
at 30% conﬂuence with 100nM siRNA duplexes using
Lipofectamine (Invitrogen) according to the manufacturer‘s
recommendations. Cells were trasfected with target-speciﬁc
Fas siRNA duplexes and control nonspeciﬁc siRNA duplex
(Dharmacon) at the same ﬁnal concentration (100nM).
After 12h, cells were treated with SLWLQY (3mgml−1)
for 24h. Fas gene silencing was conﬁrmed by western blot
analysis of Fas protein expression.
2.10. Treatment of TSGH-8301 Cells Xenografts In Vivo.
All animal experimental protocol used in this study was
approved by the Institutional Animal Care and Use Com-
mittee of the Chung Shan Medical University (IACUC,
CSMC), Taichung, Taiwan. Male BALB/c-nu mice were
purchased from the National Laboratory Animal Center
of Taiwan. They were maintained under Speciﬁc Pathogen
Free conditions and supplied with sterilized food and water.
After trypsinization, TSGH-8301 cells (1×107 per 0.2ml)
were injected subcutaneously into the ﬂanks of BALB/c-nu
mice (4–6 weeks old, 18–20g). One week later, the mice
were divided randomly into four groups of four mice each.
Mice were treated daily with 0.2ml saline as the control or
treated with the SLWLQY at doses of 0.2gkg−1,0 . 5 g k g −1
and 1gkg−1 by using a gavage tube for 30 consecutive
Table 2: Characterization of phenolic compounds of SLWLQY.
Assigned identity SLWLQY (mgg−1)
Gallic acid 228
PCA 40
EGCG 46
Caﬀeic acid 146
Rutin 671
Quercetin 143
days. To monitor the drug toxicity, body weights of mice
were measured each week. Thirty days later, the mice
were sacriﬁced, and the tumor was removed, weighed and
collected to analyze the protein expression.
3. Results
3.1. Composition of SLWLQY. To establish the composition
of SLWLQY, the contents of polyphenol were assayed. HPLC
analysis of nine kinds of standard polyphenols showed the
retention times (RT) of gallic acid, protocatechuic acid
(PCA), catechin, epigallocatechin gallate (EGCG), caﬀeic
acid, epicatechin, rutin, quercetin and naringenin were 7.68,
14.26, 20.69, 22.95, 25.24, 26.90, 33.53, 49.73 and 54.67min,
respectively (Figure 1). For the standardization of SLWLQY,
the presence of gallic acid (2.28%), PCA (0.4%), EGCG
(0.46%), caﬀeic acid (1.46%), rutin (6.71%) and quercetin
(1.43%) contained in the SLWLQY. The composition of the
SLWLQY used for the experiments was shown in Table 2.
Phenolic compounds have long been recognized as potent
antioxidants [13]. The three herbs of SLWLQY containing
the highest phenolic compounds were Paeonia lactiﬂora Pall
(gallicacid:46.9%),GlycyrrhizaUralensisFish(rutin:60.0%)
and Linderae Radix (EGCG: 68.6%) in our study (data not
shown).
3.2. Cytotoxicity of SLWLQY on Cancer Cells. Cell viability
was assayed in cultures exposed to 0.5–5mgml−1 SLWLQY
for 24h. SLWLQY showed an inhibitory eﬀect on the growth
of Huh-7, AGS, KB, TSGH-8301, MCF-7 and WRL68 cells.
SLWLQY exhibited the strongest potency of cytotoxicity
in TSGH-8301 and MCF-7 cells at a dose of 5mgml−1.
However, the death rate of WRL-68 cells (normal human
liver cell line) was lower than that of TSGH-8301 cells,
indicating that SLWLQY is less cytotoxic to normal cells
(Figure 2).
3.3. Eﬀect of SLWLQY on Inducing Apoptosis. To examine
whether the cytotoxicity of SLWLQY was due to the induc-
tion of apoptosis, cell-cycle analysis was performed by ﬂow
cytometry. After SLWLQY treatment for 24h, TSGH-8301
cells increased DNA contents of the G2/M phase at the con-
centration of 3mgml−1, as compared with vehicle controls
(13.85±1.06% versus 19.60±0.74%). We also found that
the apoptotic TSGH-8301 cells dramatically increased to a
level of 22.6% of counted cells with treatment of 5mgml−14 Evidence-Based Complementary and Alternative Medicine
0
20
40
60
80
100
120
I
n
t
e
n
s
i
t
y
(
m
v
)
01 0 2 0 3 0 4 0 5 0 6 0
Retention time (min)
1 2
3
4
5
6
7 8
9
(a)
0
5
10
15
I
n
t
e
n
s
i
t
y
(
m
v
)
01 0 2 0 3 0 4 0 5 0 6 0
Retention time (min)
1
2 4 5
7
8
(b)
Figure 1: (a) HPLC chromatogram of nine kinds of standard
polyphenols (10mgml−1). Peak: 1, gallic acid; 2, protocatechuic
acid (PCA); 3, catechin; 4, epigallocatechin gallate (EGCG); 5,
caﬀeic acid; 6, epicatechin; 7, rutin; 8, quercetin; 9, narigenin. (b)
HPLC chromatograms of free polyphenols from SLWLQY extract
(10mgml−1). Phenolic compounds correspond to peaks 1, 2, 4, 5,
6, 7 and 8 as in (a). Detector was set at 280nm. The arrow indicated
the retention time (RT) of merged both SLWLQY and diﬀerent
standards.
SLWLQYfor24hascomparedto2.9%ofthatofcontrolcells
(Figures 3(a) and 3(b)).
3.4. SLWLQY Decreases Protein Levels of G2 Regulatory CDKs
and Cyclins in Human TSGH-8301 Cells. Using immunoblot
analysis, we also observed the eﬀect of SLWLQY treatment
on the protein levels of the CDKs and cyclins during G2/M
cell-cycle progression of TSGH-8301 cells. SLWLQY strongly
decreased the expression of CDK1 (also known as cdc2)
and cyclin B1 levels in TSGH-8301 cells (Figure 4). SLWLQY
treatment at a dose of 5mgml−1 for 24h resulted in a
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Figure 2: Cell viability of various cells (Huh-7, AGS, KB, MCF-7,
WRL-68 and TSGH-8301 cells) treated with SLWLQY. Cells were
treated with or without SLWLQY under diﬀerent concentrations
(0.5–5mgml−1) for 24h. The number of viable cells in each well
was quantiﬁed by using MTT assay. The results were represented as
mean±SD, n=3.
downregulationinCDK1(0.7-fold)andcyclinB1(0.72-fold)
protein levels.
3.5. SLWLQY Induces Apoptotic Cell Death in TSGH-8301
Cells. In order to assess the mechanism of SLWLQY-induced
apoptosis, we evaluated the expressions of Bax, Bcl2,f a s ,f a s L
and caspases by western blot analysis. The expression of Bax,
a proapoptotic protein, was apparently increased (1.25-fold,
P<.05) while that of Bcl2, an antiapoptotic protein, was
dramatically decreased by a 0.52-fold in the cells treated with
5mgml −1 of SLWLQY at 24h (Figure 5(a)). The ratio of
Bax/Bcl2 was increased by SLWLQY treatment (Figure 5(b)).
Furthermore, caspases are cytosolic proteins that exist
normally as inactive precursors with higher molecular
weight (55, 32kDa). They are cleaved proteolytically into
low molecular weights (20–23kDa) when cell undergo
apoptosis [14]. In this study, the expressions of the active
form of caspase-3, caspase-9 and caspase-8 were increase
at the concentrations of 3 and 5mgml−1 of SLWLQY
(Figure 6(a)). Next, we investigated the level of cytochrome
c release in the cytosolic fraction following SLWLQY
treatment. Cytochrome c is released from the mitochondrial
intermembrane space, and is a key event in the activation
of caspase-9 and subsequently of caspase-3 [15]. The result
showed that cells exposed to SLWLQY had signiﬁcantly
increased cytochrome c in cytosolic fraction (Figure 6(a)).
In addition, activation of Fas/FasL receptor death path-
way has been shown to mediate the induction of apop-
tosis. We next attempted to determine whether SLWLQY-
mediated caspases activation was dependent on Fas/FasL
activation. As shown in Figure 6(b), SLWLQY resulted in
a signiﬁcant increased in Fas/FasL expression from 1.00 to
1.23- and 2.1-fold, respectively (P<.01). Fas/FasL signaling
was determined by studying the eﬀects of Fas gene silencing.Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: Apoptosis eﬀects of SLWLQY on TSGH-8301 cells. (a) Cells were treated with 0 (control), 1, 3 and 5mgml−1 of SLWLQY for
24h and subjected to ﬂow cytometric analysis after PI staining. (b) Quantitative assessment of the percentage of TSGH-8301 cells in cell-
cycle patterns (sub G1, G0/G1 and G2/M phase), as treated by SLWLQY, and represents the average of three independent experiments±SD.
∗P<0.05, ∗∗P<.01.
In Figure 6(c), Fas siRNA transfection largely prevented
SLWLQY-induced Fas upregulation, resulting in 50% lower
Fas protein levels in Fas knockdown cells compared with
mock-transfected controls. Mock transfection with nonspe-
ciﬁc siRNA did not aﬀect Fas expression. The eﬀect of
Fas silencing on SLWLQY-induced apoptosis was assayed
by western blot analysis of caspase-3 cleavage. Fas silencing
resulted in a signiﬁcant reduction of SLWLQY-induced
caspase-3 cleavage, conforming the functional role of Fas
signaling in SLWLQY-induced cell death.6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: SLWLQY decreases the protein expression of G2 cell-cycle regulatory CDKs and cyclins in TSGH-8301 cells. Cells were treated
with or without SLWLQY 0, 1, 3 and 5mgml−1 for 24h. Total cell lysates were prepared and subjected to SDS–PAGE followed by Western
blot, the membranes were probed with anti-cyclinB1 and Cdc2 antibody, and the results were represented by using an ECL system. β-actin
was the loading control. Results were averaged from triplicate experiments and expressed in mean±SD. ∗∗P<0.01.
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Figure 5: The expression of BCl2 family proteins (BCl2 and Bax) in TSGH-8301 cells treated with SLWLQY. (a) For western blot analysis,
TSGH-8301 cells were treated without or varying concentrations of SLWLQY for 24h. Membranes were probed with anti-Bcl2 and Bax
antibody. β-actin was the loading control. (b) The ratio of bax/BCl2 expression was indicated by SLWLQY treatment. Results were averaged
from triplicate experiments and expressed in mean±SD. ∗P<.05, ∗∗P<.01.Evidence-Based Complementary and Alternative Medicine 7
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Figure 6: SLWLQY induced apoptotic cell death in TSGH-8301 cells. Culture cells were treated without (control) or with SLWLQY at the
doses of 1, 3 and 5mgml−1 for 24h. These proteins were detected by anti-caspases-3, caspase-8, caspase-9 and cytochrome c antibodies.
The expression of cytochrome c in the cytosol and the mitochondria was assayed by immunoblotting (a) and anti-Fas/FasL antibody (b).
(c) Western blot analysis of Fas protein expression and caspase-3 cleavage in cell lysates transfected with Fas siRNA and nonspeciﬁc siRNA
as well as exposed to SLWLQY for 24h. β-actin and tubulin were the loading control. Arrows indicated the cleavage fragment of caspases.
Results were averaged from triplicate experiments and expressed in mean±SD. ∗P<.05, ∗∗P<.01.
3.6. The Anticancer Eﬀe c to fS L W L Q YI nV i v o .To verify the
anticancer eﬀects of SLWLQY in vivo,n u d em i c ee n g r a f t e d
TSGH-8301 cells were treated with or without the SLWLQY
(0.2, 0.5 and 1gkg−1) by gavage tube. As illustrated in
Figures 7(a) and 7(b), the tumor volumes of the mice
treated with SLWLQY (1gkg−1) were signiﬁcantly reduced
as compared with control, suggesting that the higher dose of
SLWLQY was able to enhance tumor regression. In order to
investigated the molecular mechanism that inhibited tumor
growthinvivo,theproteinslysatewereextractedfromtumor
tissues in each group and the apoptosis-related proteins
were determined by western blotting analysis. We found
that the expressions of Fas, FasL and Bax proteins in tumor
tissues were elevated in the groups treated with SLWLQY. In
contrast, the expression of Bcl2 was down-regulated in the
SLWLQY-treated tumor tissues (7(c)).
4. Discussion
While many anticancer agents have been developed and
used, the side eﬀects and resistance are serious problems
have to be overcome in the treatment of cancer [16].
Therefore, development of better therapeutic drugs has
become necessary. SLWLQY is characterized by the use of
mixtures of 16 herbs in a single formula. The molecular
mechanism on anti-cancer eﬀects of SLWLQY is not yet
elucidated. It has been shown that SLWLQY contains many
polyphenolic compounds, such as gallic acid (2.28%), PCA
(0.4%), EGCG (0.46%), caﬀeic acid (1.46%), rutin (6.71%),
quercetin (1.43%) and unknown polyphenols (Figure 1 and
Table 2). Phenolic or ﬂavonoid compounds possess strong
anticancer and antioxidant properties [17, 18]. Agarwal et
al. demonstrated that gallic acid could induce G2/M phase
cell-cycle arrest and apoptosis in human prostate carcinoma
DU145 cells. These ﬁndings suggested that in SLWLQY,
polyphenols could be bioactive compounds. In fact, our
unpublished data indicated that gallic acid could cause both
G2/M phase arrest and apoptosis in TSGH-8301 cells.
In this study, SLWLQY inhibited the growth of Huh-7,
AGS, KB, MCF-7, WRL68 and TSGH-8301 cells through the
induction of apoptosis (Figure 2). Among the cancerous cell
lines, SLWLQY possessed the strongest potency to induce8 Evidence-Based Complementary and Alternative Medicine
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Figure 7: The eﬀects of SLWLQY on the growth of TSGH-8301 cells in BALB/c nude mice. (a) TSGH-8301 cells were inoculated into nude
mice and treated with SLWLQY (0.2, 0.5 and 1gkg−1). The tumors were then dissected from nude mice at 4 weeks after vehicle or SLWLQY
treatment.(b)Averagetumorvolumesofvehiclevs.SLWLQY-treatednudemice(n=4)weremeasuredattheendofexperiment.(c)Western
blot analyses were performed to determine the expression of Fas, FasL, Bax and Bcl2 proteins in the tumors. Four samples were analyzed in
each group, and values represent the mean±SD. Signiﬁcance was accepted when P<.05. ∗P<.05 if compared with vehicle-treated mice.
cytotoxicity in TSGH-8301 (human bladder carcinoma
cells). However, WRL68 was less sensitive to cytotoxic eﬀect
of SLWLQY than the other cancer cells, indicating that
tumors cells are more responsive to the SLWLQY treatment.
We also have shown that SLWLQY-treated TSGH-8301 cells
are arrested irreversibly in the G2/M phase of the cell cycle
(Figure 3). In addition, no change of S phase was observed.
Cell-cycle arrest in SLWLQY-treated cells was accompanied
by a marked declined in the level of cyclinB1 and Cdk1
(Cdc2) (Figure 4). It is reasonable to postulate that SLWLQY
treatment may aﬀect activity of Cdk1/cyclin B kinase by
reducing cdk1-cyclin B1 complex formation. More specially,
Cdc2 could be phosphorylated at Thr 14 and Tyr 15 by
protein kinase, such as Myt1 and Wee1, then converted
into an inactive precursor. Whereas, Cdc2 could be also
dephosphorylated by Cdc25c and becomes inactive [19, 20].
However, more studies are needed in the future to further
support this assumption, as well as to deﬁne the role of
upstream events such as CDKI, Chk1 and Chk2 and their
regulators ATM and ATR in the observed G2/M phase arrest
by SLWLQY in TSGH-8301 cells.
In recent years, evidence has suggested that apoptosis
is important to most anticancer agents in tumor cells
[21, 22]. There are two distinct pathways that initiate
apoptosis designated as mitochondrial and receptor death
pathways [23, 24]. The mitochondrial death pathway is
controlled by members of Bcl2 and Bcl-XL proteins and
the proapoptotic Bax and Bid proteins [25, 26]. The proto-
oncogene Bcl2 encodes an inner mitochondrial protein that
reportedly antagonizes apoptosis in many tumor cells [27].
SLWLQY-induced apoptosis was found to be associated with
the downregulation of Bcl2 (Figure 5). On the contrary,
overexpression of Bax accelerates apoptotic death induced by
diﬀerent stress in many cell lines. Our founding showed that
TSGH-8301 cells expressed high level of Bax after SLWLQY
treatment to facilitate the induction of apoptosis.
For evaluation of the death receptor pathway, the roles of
Fas and FasL are well-characterized members. Engagement
of Fas by a FasL led to the formation of a protein complex
and permit execution of apoptosis by caspase-8 activation
[28]. In this study, an increase of Fas and FasL protein
was observed in the SLWLQY-treated cells (Figure 6(b)).
Release of FasL initiated apoptosis through Fas death recep-
tor which subsequently activated caspase-8 (Figure 6(a))
and cytochrome c implying an association between the
death receptor pathway and SLWLQY-induced apoptosis.
Moreover, the apoptotic death receptor pathway and mito-
chondrial death pathway could converge on activation ofEvidence-Based Complementary and Alternative Medicine 9
caspase-3. Finally, the direct link between Fas/FasL up-
regulation and SLWLQY- induced apoptosis was provided
by Fas gene silencing using RNA interference strategies
[29]. Fas silencing resulted in a signiﬁcant reduction of
caspase-3 cleavage by SLWLQY in TSGH-8301 cells. In our
study, SLWLQY induced the activation of Bax from the
mitochondria and caspase cascade activation (Figures 5 and
6). These implied that SLWLQY triggered the signaling to
induce cell apoptosis via both mitochondrion- and death
receptor-mediated pathways. In addition, our in vivo study
demonstrated that the apoptosis-related proteins (Fas/FasL,
Bax/Bcl2) were also changed in the xenografed tumors. We
also showed evidence that the antitumor activity of SLWLQY
treatmentagainstTSGH-8301cellsxenograftedinnudemice
(Figure 7). Treatment with the highest doses of SLWLQY
(1gkg−1) did not decrease the body weight when compared
to the control mice.
In summary, our ﬁndings demonstrating signiﬁcant
G2/M phase arrest and apoptosis by SLWLQY, suggest that
SLWLQY can exert anticancer activity in human bladder
cancers. However, more studies are necessary to clarify the
mechanism of SLWLQY or its isolated bioactive compounds
in the near future.
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